News Releases

Press Releases

  • 1/19/18 8:25 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced the pricing of its previously announced underwritten public offering of 2,415,278 shares of its common stock at a price to the public of $1.80 per share. In addition, PAVmed has granted the underwriters of the offering a 45-day option to purchase up to 362,292 additional shares of its common stock to cover overallotments,more...
  • 1/18/18 5:56 pm EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW)) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it intends to offer shares of common stock in an underwritten public offering. PAVmed also expects to grant to the underwriters a 45-day option to purchase additional shares of common stock to cover overallotments, if any. PAVmed intends to use the net proceeds from this offering for working capital and other generalmore...
  • 1/17/18 7:30 am EST

    Each Right Will Entitle Holder to Purchase One New Unit

    Each New Unit Will be Comprised of One Share of Common Stock and One New Series Z Warrant

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company has set the terms of its previously announced rights offering (the “Rights Offering”). Pursuant to the Rights Offering, the Company will distribute to the holders of outstanding shares of its Common Stock (Nasdaq: PAVM), for no consideration, one transferable right (the “Right”) to purchase amore...
  • 1/11/18 7:30 am EST

    Tender Offer to Extend Until February 8, 2018

    Company Also Announces Intent to Implement Rights Offering to Holders of Common Stock

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced the filing of a Tender Offer and Prospectus Supplements (the “Warrant Offer”) with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to which the cash exercise price of each tendered Series W Warrant (Nasdaq: PAVMW) (the “W Warrant”) is being reduced to $2.00 per share. The Warrant Offer begins today andmore...
  • 12/28/17 7:30 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that it intends to temporarily reduce the exercise price of the Company’s outstanding Series W Warrants (Nasdaq: PAVMW, the “Warrants”) to $2.50 per share. The Company intends to file tender offer materials (the “Offer”) providing the holders of certain warrants the opportunity to exercise their warrants at themore...
  • 12/18/17 8:00 am EST

    Device designed to replace invasive carpal tunnel surgery, addressing an estimated $1 billion market opportunity

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced that CarpX™, its minimally invasive device designed to treat carpal tunnel syndrome was recognized as one of four finalists in the Technology Innovation category of the 2017 Fierce Innovation Awards. CarpX is pictured above. “PAVmed is honored to have been recognized for technology innovation by one of the leading voicesmore...
  • 11/28/17 8:00 am EST

    Designed to replace invasive surgery and shorten recovery time; addresses an estimated $1 billion market opportunity

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced that it has filed a 510(k) premarket notification submission with the U.S. Food and Drug Administration (FDA) for its CarpX™ minimally invasive device designed to treat carpal tunnel syndrome. “We are very excited to have reached this most important milestone in PAVmed’s corporate history,” said Lishan Aklog, M.D., PAVmed’smore...
  • 11/15/17 7:30 am EST

    Conference call to be held November 16, 2017 at 4:30 p.m. Eastern time

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced financial results for the three and nine months ended September 30, 2017 and provided a business update. Management Commentary “During this quarter and in recent weeks, PAVmed has continued its inexorable march towards important developmental, regulatory and commercialization milestones,” said Lishan Aklog, M.more...
  • 11/9/17 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (NASDAQ:PAVM; PAVMW), a highly differentiated, multi-product medical device company, today announced that the Company will host a conference call on Thursday, November 16, 2017 at 4:30 p.m. Eastern time. During this call Lishan Aklog, M.D., the Company’s Chairman and Chief Executive Officer, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, themore...
  • 10/10/17 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (NASDAQ:PAVM; PAVMW), a highly differentiated, multi-product medical device company, today announced that Dennis McGrath, PAVmed’s Chief Financial Officer, will present at the Dawson James Securities 3rd Annual Small Cap Growth Conference on Thursday, October 19, 2017 at 1:00 p.m. Eastern time. Mr. McGrath will provide a corporate overview, discuss the Company’s innovative business model and review PAVmed’s lead products. Themore...

SEC Filings

Click Here to view PAVmed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation

PROXY MATERIALS

Click Here to view the Proxy Statement for PAVmed Inc 2017 Annual Meeting

Click Here to view the Annual Report for PAVmed Inc 2017 Annual Meeting